Overcoming the formulation obstacles towards targeted chemotherapy:: In vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles

被引:31
作者
Debotton, Nir [1 ]
Parnes, Marcela [1 ]
Kadouche, Jean [2 ]
Benita, Simon [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel
[2] MAT Ltd, MAT Biopharm, F-91030 Evry, France
关键词
nanoparticles; immunonanoparticles; monoclonal antibodies; docetaxel; paclitaxel palmitate; pharmacokinetics; anti-tumor;
D O I
10.1016/j.jconrel.2008.01.014
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of this study was to design a new one step conjugation of monoclonal antibodies (MAbs) to surface activated pegylated polyester nanoparticles (NPs) and evaluate the pharmacokinetic profile and therapeutic effect of paclitaxel palmitate (pcpl) loaded anti-HER2 immunoNPs in mice as compared to pcpl solution and NPs following IV injection. The density of the antibody conjugated to the NPs was found to be around 35 MAbs/NP (70% coupling efficiency). In vitro cell culture studies showed good binding and uptake results when immunoNPs were incubated with PC-3 and CAPAN-1 cell lines. Both pept NPs and immunoNPs showed significant increased t1/2, C-max and AUC values as compared to the values of pcpl solution in mice. There was no significant difference in the C-max and AUC values between pcpl NPs and pcpl immunoNPs. However, the immunoNPs concentrated much less in the liver and spleen than NPs. The pharmacokinetic behavior of the immunoNPs was markedly different from the pharmacokinetic profile of the naked MAb showing that the MAb lost its intrinsic molecular pharmacokinetic properties following conjugation to the NPs. The immunoNPs elicited a significant anti-tumor activity as compared to the pcpl solution and NPs, although the tumor growth was not fully inhibited. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:219 / 230
页数:12
相关论文
共 48 条
[1]   Monoclonal antibody therapy of cancer [J].
Adams, GP ;
Weiner, LM .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157
[2]  
Akasaka Y, 1988, Drug Des Deliv, V3, P85
[3]   Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes [J].
Balthasar, S ;
Michaelis, K ;
Dinauer, N ;
von Briesen, H ;
Kreuter, J ;
Langer, K .
BIOMATERIALS, 2005, 26 (15) :2723-2732
[4]   STEALTH ME.PEG-PLA NANOPARTICLES AVOID UPTAKE BY THE MONONUCLEAR PHAGOCYTES SYSTEM [J].
BAZILE, D ;
PRUDHOMME, C ;
BASSOULLET, MT ;
MARLARD, M ;
SPENLEHAUER, G ;
VEILLARD, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (04) :493-498
[5]   A NEW IMMUNOREAGENT FOR CELL LABELING - CD3 MONOCLONAL-ANTIBODY COVALENTLY COUPLED TO FLUORESCENT POLYMETHACRYLIC NANOPARTICLES [J].
BOUREL, D ;
ROLLAND, A ;
LEVERGE, R ;
GENETET, B .
JOURNAL OF IMMUNOLOGICAL METHODS, 1988, 106 (02) :161-167
[6]   Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery [J].
Cheng, Jianjun ;
Teply, Benjamin A. ;
Sherifi, Ines ;
Sung, Josephine ;
Luther, Gaurav ;
Gu, Frank X. ;
Levy-Nissenbaum, Etgar ;
Radovic-Moreno, Aleksandar F. ;
Langer, Robert ;
Farokhzad, Omid C. .
BIOMATERIALS, 2007, 28 (05) :869-876
[7]   Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers [J].
Cho, CS ;
Kobayashi, A ;
Takei, R ;
Ishihara, T ;
Maruyama, A ;
Akaike, T .
BIOMATERIALS, 2001, 22 (01) :45-51
[8]   Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes [J].
Dinauer, N ;
Balthasar, S ;
Weber, C ;
Kreuter, J ;
Langer, K ;
von Briesen, H .
BIOMATERIALS, 2005, 26 (29) :5898-5906
[9]   Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel [J].
Dong, Yuancai ;
Feng, Si-Shen .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2006, 78A (01) :12-19
[10]  
El Hilali N, 2005, CLIN CANCER RES, V11, P1253